Resistance to Cyclophilin Inhibitors
Publisher
Springer New York
Reference114 articles.
1. Alberti M, Chuang WL, Flisiak R et al (2012) Alisporivir (ALV) plus peg-interferon/ribavirin (PR) in HCV G1 treatment-experienced patients achieves primary endpoint with superior efficacy at treatment week 12 compared to retreatment with PR. J Hepatol 56:S553–S554. Abstract 1406
2. Alter MJ (2007) Epidemiology of hepatitis C virus infection. World J Gastroenterol 13:2436–2441
3. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144:705–714
4. Balagopal A, Thomas DL, Thio CL (2010) IL28B and the control of hepatitis C virus infection. Gastroenterology 139(6):1865–1876. doi:10.1053/j.gastro.2010.10.004. Epub 2010 Oct 13. Review
5. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T et al (2008) Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3/4A protease inhibitors in treatment-naive subjects. J Infect Dis 198(6):800–807